We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
It was a big day for Baxalta’s hemophilia franchise on Friday, with the company announcing that it had nabbed marketing authorization in the EU for Obizur, and the FDA giving its approval for Adynovate. Read More
Members of an FDA advisory committee unanimously recommended Merck’s anesthesia candidate sugammadex for approval, a win for the drug giant, which saw the candidate previously held back over safety and data integrity concerns. Read More